This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Ono Pharmaceutical Co. (OPHLF) Upgraded to Buy: Here's Why
by Zacks Equity Research
Ono Pharmaceutical Co. (OPHLF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Sell Stocks for June 2nd
by Zacks Equity Research
OPHLF, TOELY and TLYS have been added to the Zacks Rank #5 (Strong Sell) List on June 2, 2023.
3 Reasons Why Ono Pharmaceutical Co. (OPHLF) Is a Great Growth Stock
by Zacks Equity Research
Ono Pharmaceutical Co. (OPHLF) possesses solid growth attributes, which could help it handily outperform the market.
Ono Pharmaceutical Co. (OPHLF) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Ono Pharmaceutical Co. (OPHLF) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Has Acadia Healthcare (ACHC) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Acadia Healthcare (ACHC) and Ono Pharmaceutical Co. (OPHLF) have performed compared to their sector so far this year.
Is Homology Medicines (FIXX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Homology Medicines (FIXX) and Ono Pharmaceutical Co. (OPHLF) have performed compared to their sector so far this year.
Pacira (PCRX) Gets FDA Nod for Exparel in Pediatric Patients
by Zacks Equity Research
The FDA approves Pacira's (PCRX) Exparel for use in patients aged six years and older for single-dose infiltration to produce postsurgical local analgesia.
KemPharm (KMPH) Soars on FDA Nod for ADHD Treatment, Azstarys
by Zacks Equity Research
The FDA approves KemPharm's (KMPH) NDA for Azstarys for the treatment of attention deficit hyperactivity disorder in patients aged six years and older. Shares rise.
Aerie (AERI) Rises Despite Q4 Earnings Miss, Revenues Top Mark
by Zacks Equity Research
Aerie (AERI) up more than 16% despite reporting a wider-than-expected loss in the fourth quarter of 2020. Revenues beat estimates.
Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
Pacira's (PCRX) earnings in the fourth quarter of 2020 beat estimates while revenues miss the same. Exparel sales rise year over year.
CytoDyn Signs MOU With NIH of Mexico for Coronavirus Study
by Zacks Equity Research
CytoDyn's (CYDY) shares rise more than 20% as it inks an MOU with NIH of Mexico to conduct a COVID-19 study on leronlimab.
Amgen: Phase III Data on Hyperparathyroidism Drug Published
by Zacks Equity Research
Amgen Inc. (AMGN) announced that data from three phase III studies on its pipeline candidate, Parsabiv (etelcalcetide), were published in the Journal of the American Medical Association (JAMA).